



AHCL/ SE/ 40/2023-24

November 10 2023

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031 Symbol : AMRUTANJAN	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 Scrip Code: 590006
---	---

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 30, 33 and 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**November 10, 2023**) had inter-alia:

- (i) Approved the Un-audited Financial Results for the quarter and half year ended September 30, 2023. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared First Interim Dividend of Re.1/- per share for the financial year 2023-24 on the Equity Shares of the Company.
- (iii) Recommended Re-Appointment of Mr. S. Sambhu Prasad as Chairman and Managing Director of the Company for a further period of five years from 01-04-2024 to 31-03-2029 which is subject to approval of the Shareholders through Postal Ballot.

Further, in compliance of Regulation 42 of SEBI LODR, it is hereby informed that Company has fixed 23rd November 2023 as record date for payment of first Interim dividend for the financial year 2023-24 to the members whose name appear in the register of Members and as the beneficial owners as per the details received from National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) as on the record date.

The Board Meeting commenced at 04.00 PM and concluded at 08.00 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

(M Srinivasan)
Company Secretary & Compliance Officer

Encl:

1. Un-audited Standalone Financials Results for the quarter and half year ended September 30 2023
2. Limited Review Report

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel : +91-44 - 2499 4465
+91-44 - 2466 9000
Fax : +91-44 - 2499 4585

E-mail : customercare@amrutanjan.com
Web Site : www.amrutanjan.com
Toll Free No. : 1 - 800 - 425 - 4545
CIN - L24231TN1936PLC000017

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of assets and liabilities

(Rs. in Lakhs)

S. No.	Particulars	As at	As at
		30 September 2023 (Unaudited)	31 March 2023 (Audited)
A	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	4,714.41	4,561.68
	(b) Right-of-use assets	60.18	81.42
	(c) Intangible assets	211.00	248.39
	(d) Capital work-in progress	20.65	111.44
	(e) Financial assets		
	Investments	2.31	2.31
	Other financial assets	1,767.86	4,303.12
	(f) Tax assets (Net)	585.80	367.63
	(g) Deferred tax assets (Net)	404.77	425.44
	(h) Other non-current assets	208.82	153.57
	Total non-current assets	7,975.80	10,255.00
2	Current assets		
	(a) Inventories	3,089.03	2,882.51
	(b) Financial assets		
	Investments	504.90	514.69
	Trade receivables	3,348.90	3,302.03
	Cash and cash equivalents	925.96	490.28
	Other bank balances	4,082.69	6,541.31
	Other financial assets	14,973.84	11,709.87
	(c) Other current assets	604.29	513.64
	Total current assets	27,529.61	25,954.33
	Total assets (1+2)	35,505.41	36,209.33
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	289.11	292.31
	(b) Other equity	25,911.19	28,784.88
	Total equity	26,200.30	29,077.19
	Liabilities		
2	Non-current liabilities		
	(a) Financial liabilities		
	Lease liabilities	37.10	40.40
	Other financial liabilities	16.60	16.60
	(b) Provisions	706.58	773.93
	Total non-current liabilities	760.28	830.93
3	Current liabilities		
	(a) Financial liabilities		
	Lease liabilities	29.49	50.51
	Trade payables		
	total outstanding dues of micro, small and medium enterprises	464.49	608.44
	total outstanding dues of creditors other than micro, small and medium enterprises	5,559.77	4,135.17
	Other financial liabilities	855.63	204.13
	(b) Other current liabilities	1,357.67	784.88
	(c) Provisions	277.78	518.08
	Total current liabilities	8,544.83	6,301.21
	Total equity and liabilities (1+2+3)	35,505.41	36,209.33



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter and half year ended 30 September 2023

	Particulars	Amount in INR Lakhs					
		Quarter ended			Half year ended		Year ended
		30 September 2023 (Unaudited)	30 June 2023 (Unaudited)	30 September 2022 (Unaudited)	30 September 2023 (Unaudited)	30 September 2022 (Unaudited)	31 March 2023 (Audited)
I	Income						
	Revenue from operations	9,931.16	7,786.30	11,071.93	17,717.46	18,167.35	37,963.60
	Other income	394.75	368.63	303.24	763.38	604.49	1,454.17
	Total income	10,325.91	8,154.93	11,375.17	18,480.84	18,771.84	39,417.77
II	Expenses						
	(a) Cost of materials consumed	2,327.71	2,238.05	2,880.17	4,565.76	5,553.37	10,517.33
	(b) Purchases of stock-in-trade	2,916.88	1,893.31	2,203.46	4,810.19	3,543.06	7,853.27
	(c) Changes in inventories of finished goods and stock-in-trade	(153.20)	(70.34)	311.78	(223.65)	(202.15)	(172.74)
	(d) Employee benefits expense	1,181.02	1,136.97	1,231.15	2,317.99	2,442.13	4,881.02
	(e) Advertisement and selling expenditure	1,705.24	653.96	1,567.42	2,359.20	2,556.61	5,256.16
	(f) Finance cost	2.97	2.39	1.95	5.36	4.39	7.71
	(g) Depreciation and amortisation expense	155.44	139.20	152.06	294.64	258.76	521.15
	(h) Other expenses	1,269.31	1,218.43	1,285.12	2,487.74	2,348.56	5,187.33
	Total expenses	9,405.37	7,211.97	9,633.11	16,617.33	16,504.73	34,053.23
III	Profit before tax (I - II)	920.54	942.96	1,742.06	1,863.51	2,267.11	5,364.54
IV	Tax expenses	235.62	241.48	465.56	477.10	624.21	1,381.05
V	Profit after tax (III- IV)	684.92	701.48	1,276.50	1,386.41	1,642.90	3,983.49
VI	Other comprehensive income						
	Items that will not be reclassified subsequently to profit or loss						
	Re-measurement gain/(loss) on defined benefit plans, net of taxes	10.75	6.32	(45.97)	17.07	(118.56)	(121.91)
	Other comprehensive income/ (loss) for the period, net of taxes	10.75	6.32	(45.97)	17.07	(118.56)	(121.91)
VII	Total comprehensive income for the period (V+VI)	695.67	707.80	1,230.53	1,403.48	1,524.34	3,861.58
	Paid-up equity share capital (Face value Re. 1/- each)	289.11	292.31	292.31	289.11	292.31	292.31
	Earnings per equity share for continuing operations						
	Basic earnings per share (INR)	2.36	2.40	4.37	4.77	5.63	13.65
	Diluted earnings per share (INR)	2.36	2.39	4.36	4.77	5.62	13.63
	<i>See accompanying notes to unaudited financial results</i>	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

- The above unaudited financial results for the quarter and six months ended 30 September 2023 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 10 November 2023. The above results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.
- These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The shareholders of the Company at its Annual General Meeting held on 21 September 2023, has approved final dividend of Rs 2.60/- per equity share of face value Re 1 each for the financial year ended 31 March 2023.
- During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP Trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company.
- After obtaining the approval of the Board of Directors in their meeting held on 30 June 2023, the buy back of 320,000 Equity Shares of Rs 1/- each (Representing 1.09% of the total number of paid up equity shares of the company) from the shareholders of the company on proportionate basis, by way of tender offer route at a price of Rs 900/- per share for an aggregate amount of Rs 2,880.00 lakhs (9.80% of the paid up capital and free reserves), was initiated in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulation, 1998 and related taxes amounting to Rs 670.18 lakhs has been paid in accordance with the provisions of the Income Tax Act, 1961. The buy back procedures were completed on 03 August 2023.
- The unaudited financial results of the Company for the quarter and six months ended 30 September 2023 has been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website.
- Segment reporting in the unaudited financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

Amount in INR Lakhs

Particulars	Quarter ended			Half year ended		Year ended
	30 September 2023 (Unaudited)	30 June 2023 (Unaudited)	30 September 2022 (Unaudited)	30 September 2023 (Unaudited)	30 September 2022 (Unaudited)	31 March 2023 (Audited)
1 Segment revenue						
a OTC Products	9,408.19	6,614.67	10,423.37	16,022.86	16,664.72	34,511.23
b Beverages	484.32	1,128.94	600.28	1,613.26	1,396.68	3,246.33
c Others	38.65	42.69	48.28	81.34	105.95	206.04
Total	9,931.16	7,786.30	11,071.93	17,717.46	18,167.35	37,963.60
2 Segment results						
a OTC Products	755.59	668.19	1,704.77	1,423.78	2,147.00	4,880.03
b Beverages	(63.77)	(35.50)	(223.55)	(119.26)	(367.01)	(393.17)
c Others	(45.06)	(24.38)	(18.77)	(69.44)	(32.23)	(73.06)
Total	626.76	608.31	1,462.45	1,235.08	1,747.76	4,413.80
Less: Finance cost	2.97	2.39	1.95	5.36	4.39	7.71
Add: Other unallocable expenditure net of interest income	296.75	337.04	281.56	633.79	523.74	958.45
Total profit before tax	920.54	942.96	1,742.06	1,863.51	2,267.11	5,364.54
3 Segment assets						
a OTC Products	9,552.89	8,670.31	10,486.91	9,552.89	10,486.91	9,000.88
b Beverages	2,099.79	2,218.22	2,325.41	2,099.79	2,325.41	2,180.65
c Others	20.58	28.38	52.13	20.58	52.13	36.25
d Unallocated assets	23,832.15	25,965.88	24,006.25	23,832.15	24,006.25	24,991.55
Total	35,505.41	36,882.79	36,870.70	35,505.41	36,870.70	36,209.33
4 Segment liabilities						
a OTC Products	7,494.75	5,584.82	7,187.78	7,494.75	7,187.78	5,265.52
b Beverages	583.96	849.26	977.78	583.96	977.78	1,031.87
c Others	35.92	47.23	51.83	35.92	51.83	39.95
d Unallocated liabilities	1,190.48	605.76	1,355.17	1,190.48	1,355.17	794.80
Total	9,305.11	7,087.07	9,572.56	9,305.11	9,572.56	7,132.14
Total capital employed in the Company	26,200.30	29,795.72	27,298.14	26,200.30	27,298.14	29,077.19

For Amrutanjan Health Care Limited



S Sambhu Prasad
Chairman & Managing Director
DIN: 00015729

Date: 10 November 2023
Place: Chennai

AMRUTANJAN HEALTH CARE LIMITED

CIN No : L24231TN1936PLC000017

Registered Office: No. 103 (Old No. 42-45), Luz Church Road

Mylapore, Chennai - 600 004

Statement of Cash flows for the half year ended 30 September 2023

(Rs. in Lakhs)

Particulars	For the half year ended 30 September 2023	For the half year ended 30 September 2022	For the year ended 31 March 2023
	(Unaudited)	(Unaudited)	Audited
Cash flow from operating activities			
Profit before income tax	1,863.51	2,267.11	5,364.54
Adjustments for:			
Depreciation and amortisation expense	294.64	258.76	521.15
Profit on sale of property, plant and equipment	(15.25)	-	(2.69)
Share based compensation expense	21.50	21.59	43.76
Loss allowance on trade receivables	83.81	22.42	46.35
Change in fair value of investments	9.79	9.79	20.48
Gain on sale of investments	-	-	-
Interest income on deposits with banks and financial institutions	(688.13)	(523.32)	(1,126.59)
Interest income on debt instruments	(20.58)	(29.35)	(51.71)
Excess provision written back, (net)	(37.36)	(27.76)	(234.60)
Unrealised gain on foreign exchange differences	-	(5.87)	-
Finance costs	4.45	4.39	7.71
Operating profit before working capital / other changes	1,516.38	1,997.76	4,588.40
Working capital adjustments:			
(Increase) / Decrease in trade receivables	(130.68)	(907.89)	477.22
(Increase) / Decrease in other current and non-current assets	(94.73)	(258.24)	29.67
(Increase) / Decrease in other financial assets	(5.17)	1.24	(7.31)
Decrease / (Increase) in inventories	(206.52)	(439.42)	(282.44)
(Decrease) / Increase in other current/non-current financial liabilities	(86.20)	501.73	(364.01)
(Decrease) / Increase in provisions	(45.89)	59.35	18.45
Increase / (Decrease) in trade payables	1,318.01	607.26	(1,066.67)
Increase / (Decrease) in other current liabilities	572.79	(179.22)	134.76
	1,321.61	(615.19)	(1,060.33)
Cash generated from operating activities	2,837.99	1,382.57	3,528.07
Less: Income tax paid (net)	(919.30)	(1,087.90)	(1,606.26)
Net cash generated from operating activities (a)	1,918.69	294.67	1,921.81
Cash flow from investing activities			
Purchase or construction of property, plant and equipment, intangible assets, capital work in progress, intangible assets under development	(350.75)	(805.64)	(892.67)
Proceeds from sale of Property, plant and equipment	15.25	-	4.36
Redemption/ (Investment) in bank deposits and financial institutions	2,649.17	224.39	(1,232.48)
Interest received on deposits with banks and financial institutions	492.91	471.90	1,039.91
Proceeds from sale/redemption of investments	-	651.53	750.02
Interest received on debt instruments	41.04	75.19	83.36
Net cash used in investing activities (b)	2,847.62	817.37	(247.50)
Cash flow from financing activities			
Dividend paid	(751.68)	(760.00)	(1,344.62)
Payment for buyback of shares (including the tax effects)	(3,550.18)	-	-
Payment of lease liabilities	(28.77)	(30.08)	(58.03)
Net cash used in financing activities (c)	(4,330.63)	(790.08)	(1,402.65)
Net (decrease) in cash and cash equivalents (a) + (b) + (c)	435.68	321.86	271.66
Cash and cash equivalents at the beginning of the year	490.28	218.62	218.62
Effect of exchange rate fluctuations on cash held	-	0.12	-
Cash and cash equivalents at the end of the year	925.96	540.70	490.28
Components of cash and cash equivalents			
Cash on hand	6.63	5.02	2.93
Bank balances	919.33	535.68	487.35
Cash and cash equivalents as per Statement of assets and liabilities	925.96	540.70	490.28



B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st and 2nd Floors
No. 1, Harrington Road, Chetpet
Chennai – 600 031, India
Telephone: +91 44 4608 3100
Fax: +91 44 4608 3199

Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 30 September 2023 and year to date results for the period from 1 April 2023 to 30 September 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as "the Company") for the quarter ended 30 September 2023 and year to date results for the period from 1 April 2023 to 30 September 2023 ("the Statement") in which are included interim financial results of Amrutanjan Health Care Limited ESOP Trust ("ESOP Trust").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes the interim financial results of ESOP Trust which has not been reviewed, whose interim financial results reflect total assets (before consolidation adjustments) of INR 452.32 Lakhs as at 30 September 2023, total revenues (before consolidation adjustments) of INR Nil and total net (loss) after tax (before consolidation adjustments) of INR (0.02) Lakhs for the quarter ended 30 September 2023 and for the period from 1 April 2023 to 30 September 2023 respectively, and cash outflow (before consolidation adjustments) of INR 0.02 Lakhs for the period from 1 April 2023 to 30 September 2023 as considered in the Statement. According to the information and explanations given to us by the management, these interim financial results are not material to the Company.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No.:101248W/W-100022

R Kalyana Sundara Rajan
Partner

Membership No.: 221822
UDIN:23221822BGYQPH4999

Chennai
10 November 2023

Registered Office: